Cost‐Effectiveness of Donanemab for Early Alzheimer Disease in Australia

Key Points

• Evaluate the cost-effectiveness of Donanemab for early Alzheimer Disease in the Australian context.
• Assessment of clinical benefits of Donanemab
• Evaluation against Australian cost-effectiveness thresholds
• Consideration of economic evidence, equity, and healthcare sustainability
• Donanemab shows clinical benefits but may not meet cost-effectiveness standards
• Highlights the need for balanced policymaking
• Calls for further research using real-world evidence

Abstract